Editas Medicine Q1 2026: EDIT-401 Shows ≥90% LDL-C Reduction in Primates for Familial Hypercholesterolemia

Editas Medicine reports Q1 2026 financial results alongside a significant clinical pipeline update. The headline development is EDIT-401, an in vivo CRISPR-Cas9 gene editing candidate targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) for heterozygous familial hypercholesterolemia (HeFH), a hereditary condition causing severely elevated LDL cholesterol and dramatically increased cardiovascular risk from birth. New preclinical data presented at ASGCT 2026, TIDES USA, and EAS conferences show EDIT-401 achieves ≥90% LDL-C reduction in non-human primate (NHP) models following a single dose — a highly durable effect maintained through the observation window. Editas expects to file an IND and initiate the first-in-human clinical trial for EDIT-401 in the second half of 2026, targeting adult HeFH patients who are inadequately controlled on existing lipid-lowering therapies (statins, ezetimibe, PCSK9 monoclonal antibodies). If the NHP data translates to humans, a single CRISPR treatment could achieve permanent LDL reduction — potentially replacing lifetime pharmacotherapy. In parallel, Editas continues EDIT-301 (base-edited hematopoietic stem cells for SCD and TDT), with human data expected in 2026, and preclinical EDIT-402 and EDIT-403 programs at early stages. Q1 2026 financials: cash position of approximately $280 million providing runway into mid-2027; operating loss of approximately $52 million for the quarter.